Cited 11 times in
Nonlytic Fc-fused IL-7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조상래 | - |
dc.date.accessioned | 2014-12-18T08:50:36Z | - |
dc.date.available | 2014-12-18T08:50:36Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/87053 | - |
dc.description.abstract | Improvement to the immunogenicity of DNA vaccines was evaluated in a Mycobacterium tuberculosis (MTB) infection mouse model examining the combined effects of nonlytic Fc-fused IL-7 DNA (IL-7-nFc) and Flt3-ligand fused Mtb32 (F-Mtb32) DNA. Mice were treated with conventional chemotherapy for 6 weeks from 4 weeks after aerosol infection of MTB. Following the start of chemotherapy, DNA immunizations were administered five times with 2-week intervals. Coadministration of IL-7-nFc and F-Mtb32 DNA given during chemotherapy synergistically enhanced the magnitude of Mtb32-specific T cell responses and sustained for one-year after the last immunization assessed by IFN-γ ELISPOT assay. After dexamethasone treatment, a significantly reduced MTB reactivation was observed in mice received both IL-7-nFc and F-Mtb32 DNA, compared with F-MTb32 DNA alone or with control mice. In addition, mice treated with IL-7-nFc and F-Mtb32 DNA together showed improved lung pathology and reduced pulmonary inflammation values relative to F-Mtb32 DNA or saline injected mice. Intracellular cytokine staining revealed that the protection levels induced by combination therapy with IL-7-nFc and F-Mtb32 DNA was associated with enhanced Mtb32-specific IFN-γ secreting CD4+ T cell responses and CD8+ T cell responses stimulated with CTL epitope peptide in the lungs and spleens. These data suggest that IL-7-nFc as a novel TB adjuvant may facilitate therapeutic TB DNA vaccine to the clinics through significant enhancement of codelivered DNA vaccine-induced T cell immunity. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | VACCINE | - |
dc.publisher | VACCINE | - |
dc.relation.isPartOf | VACCINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antigens, Bacterial/genetics | - |
dc.subject.MESH | Antigens, Bacterial/immunology* | - |
dc.subject.MESH | CD4-Positive T-Lymphocytes/immunology | - |
dc.subject.MESH | CD8-Positive T-Lymphocytes/immunology | - |
dc.subject.MESH | Drug Synergism | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Immunoglobulin Fc Fragments/genetics | - |
dc.subject.MESH | Immunoglobulin Fc Fragments/immunology* | - |
dc.subject.MESH | Interferon-gamma/biosynthesis | - |
dc.subject.MESH | Interleukin-7/genetics | - |
dc.subject.MESH | Interleukin-7/immunology* | - |
dc.subject.MESH | Membrane Proteins/genetics | - |
dc.subject.MESH | Membrane Proteins/immunology* | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Inbred C57BL | - |
dc.subject.MESH | Mycobacterium tuberculosis/immunology | - |
dc.subject.MESH | Tuberculosis Vaccines/immunology* | - |
dc.subject.MESH | Tuberculosis, Pulmonary/immunology | - |
dc.subject.MESH | Tuberculosis, Pulmonary/prevention & control* | - |
dc.subject.MESH | Vaccination | - |
dc.subject.MESH | Vaccines, DNA/immunology* | - |
dc.title | Nonlytic Fc-fused IL-7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Microbiology (미생물학) | - |
dc.contributor.googleauthor | So-Shin Ahn | - |
dc.contributor.googleauthor | Bo-Young Jeon | - |
dc.contributor.googleauthor | Seong-Jeong Park | - |
dc.contributor.googleauthor | Dong-Hoon Choi | - |
dc.contributor.googleauthor | Sun-Hwa Ku | - |
dc.contributor.googleauthor | Sang-Nae Cho | - |
dc.contributor.googleauthor | Young-Chul Sung | - |
dc.identifier.doi | 10.1016/j.vaccine.2013.04.029 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03824 | - |
dc.relation.journalcode | J02776 | - |
dc.identifier.eissn | 1358-8745 | - |
dc.identifier.pmid | 23624092 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0264410X13004684 | - |
dc.subject.keyword | Tuberculosis | - |
dc.subject.keyword | IL-7-nFc | - |
dc.subject.keyword | Mtb32 | - |
dc.subject.keyword | DNA vaccine | - |
dc.subject.keyword | Adjuvant | - |
dc.subject.keyword | Immunotherapy | - |
dc.contributor.alternativeName | Cho, Sang Nae | - |
dc.contributor.affiliatedAuthor | Cho, Sang Nae | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 31 | - |
dc.citation.number | 27 | - |
dc.citation.startPage | 2884 | - |
dc.citation.endPage | 2890 | - |
dc.identifier.bibliographicCitation | VACCINE, Vol.31(27) : 2884-2890, 2013 | - |
dc.identifier.rimsid | 32128 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.